Details der Publikation - A clinical trial to evaluate long-term treatment with a drug called secukinumab inadult patients who are diagnosed with moderate to severe hidradenitissuppurativa (long term skin disease characterized by the occurrence ofinflamed and swollen lumps) and that participated in the previous clinical studies named CAIN457M2301 and CAIN457M2302.

A clinical trial to evaluate long-term treatment with a drug called secukinumab inadult patients who are diagnosed with moderate to severe hidradenitissuppurativa (long term skin disease characterized by the occurrence ofinflamed and swollen lumps) and that participated in the previous clinical studies named CAIN457M2301 and CAIN457M2302. : A Multicenter, Double-blind, Randomized Withdrawal extension study of subcutaneous secukinumab to demonstrate long-term efficacy, safety and tolerability in subjects with moderate to severe hidradenitis suppurativa

Medienart:	Klinische Studie

Erscheinungsjahr:	2023
Erschienen:	2023

Enthalten in:	WHO International Clinical Trials Registry Platform - (2023) vom: 21. Juni Zur Gesamtaufnahme - year:2023

Sprache:	Englisch

Links:	Volltext [kostenfrei]

Themen:	610 Medical Condition: hidradenitis suppurativa MedDRA version: 20.0Level: LLTClassification code 10020041Term: Hidradenitis suppurativaSystem Organ Class: 100000004858;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] Phase: Phase 3 Recruitment Status: Authorised-recruitment may be ongoing or finished Study Type: Interventional

Anmerkungen:	WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 20-12-2019, Last updated: 2023-06-29

ICTRP ID:	EUCTR2019-003230-17-ES CAIN457M2301E1 2019-003230-17-GB

Förderinstitution / Projekttitel:

PPN (Katalog-ID):	WHO005700604

Internformat


LEADER	01000caa a22002652 4500
001	WHO005700604
003	DE-627
005	20230629100632.0
007	cr uuu---uuuuu
008	210507s2023 xx \|\|\|\|\|o 00\| \|\|eng c
035			\|a (DE-627)WHO005700604
035			\|a (UBBS_Klinische_Studien_WHO)EUCTR2019-003230-17-ES
035			\|a (UBBS_Klinische_Studien_WHO)CAIN457M2301E1
035			\|a (UBBS_Klinische_Studien_WHO)2019-003230-17-GB
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
245	1	0	\|a A clinical trial to evaluate long-term treatment with a drug called secukinumab inadult patients who are diagnosed with moderate to severe hidradenitissuppurativa (long term skin disease characterized by the occurrence ofinflamed and swollen lumps) and that participated in the previous clinical studies named CAIN457M2301 and CAIN457M2302. \|b A Multicenter, Double-blind, Randomized Withdrawal extension study of subcutaneous secukinumab to demonstrate long-term efficacy, safety and tolerability in subjects with moderate to severe hidradenitis suppurativa
264		1	\|c 2023
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 20-12-2019, Last updated: 2023-06-29
650		4	\|a Medical Condition: hidradenitis suppurativa MedDRA version: 20.0Level: LLTClassification code 10020041Term: Hidradenitis suppurativaSystem Organ Class: 100000004858;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
650		4	\|a Study Type: Interventional
650		4	\|a Phase: Phase 3
650		4	\|a Recruitment Status: Authorised-recruitment may be ongoing or finished
650		4	\|a 610
773	0	8	\|i Enthalten in \|t WHO International Clinical Trials Registry Platform \|g (2023) vom: 21. Juni
773	1	8	\|g year:2023 \|g day:21 \|g month:06
856	4	0	\|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-003230-17 \|z kostenfrei \|3 Volltext
912			\|a GBV_CTG
951			\|a AR
952			\|j 2023 \|b 21 \|c 06

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände